Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 887-895

  Akbar, Sheikh Mohammad Fazle ^a,b   Yoshida, Osamu ^b   Chen, Shiyi ^b   Cesar, Aguilar Julio ^c   Abe, Masanori ^b   Matsuura, Bunzo ^b   Hiasa, Yoichi ^b   Onji, Morikazu ^b  

^a Tokyo Shina gawa Hospital   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DENDRITIC CELLS; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; SPLEEN; T-LYMPHOCYTES; VACCINATION; YOUNG ADULT;

EID: 77957336889     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1637     Document Type: Article

References (29)

1. Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections; the past, the present and the future. Rev Med Virol 2008; 18:19-34.
2. Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systemic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009; 150:111-124.
3. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27:152-160.
4. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963-971.
5. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19:17-26. (Pubitemid 40204344)
6. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006; 5:707-716.
7. Onji M, Akbar SM. Dendritic Cell in Clinics. 2nd ed. Tokyo: Springer 2008.
8. van der Molen RG, Sprengers D, Binda RS, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40:738-746.
9. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
10. Jiang WZ, Fan Y, Liu X, et al. Therapeutic potential of dendritic cell-based immunization against HBV transgenic mice. Antiviral Res 2008; 77:50-55.
11. Akbar SM, Furukawa S, Hasebe A, Horiike N, Michitaka K, Onji M. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer. Int J Mol Med 2004; 14:295-299.
12. Araki K, Miyazaki J, Hino O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci U S A 1989; 86:207-211.
13. Niiya T, Akbar SM, Yoshida O, et al. Impaired dendritic cell function resulting from chronic undernutrition disrupts the antigen-specific immune response in mice. J Nutr 2007; 137:671-675.
14. Akbar SM, Onji M, Inaba K, Yamamura K, Ohta Y. Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells. Immunology 1993; 78:468-475.
15. Yoshida O, Akbar F, Miyake T, et al. Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell. Clin Exp Immunol 2008; 152:174-181.
16. Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 2007; 47:60-66.
17. Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy and decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 2005; 40:157-163.
18. Betancourt AA, Delgado CA, Estévez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394-401.
19. Akbar SM, Abe M, Masumoto T, Horiike N, Onji M. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol 1999; 30:755-764.
20. Hasebe A, Akbar SM, Furukawa S, Horiike N, Onji M. Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol 2005; 139:35-42.
21. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
22. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995; 49:105-109.
23. Horiike N, Akbar SM, Michitaka K, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005; 32:156-161.
24. Akbar SM, Yoshida O, Furukawa S, Hiasa Y, Horiike N, Onji M. Induction of antigen-specific humoral and cellular immune responses by antigen-pulsed dendritic cells in hepatitis B vaccine nonresponders and patients with chronic hepatitis B. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. Abstract 110.
25. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005; 42:289-294.
26. Vanlandschoot P, Cao T, Leroux-Roels G. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res 2003; 60:67-74.
27. Lee BO, Tucker A, Frelin L, et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol 2009; 182:6670-6681.
28. Vanlandschoot P, Van Houtte F, Hoek F, Nieuwland R, Leroux-Roels G. Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity. J Med Virol 2003; 70:513-519.
29. Aguilar JC, Lobaina Y, Muzio V, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004; 82:539-546.